anti-rage (receptor advanced glycation end products) antibody improves diabetic retinopathy in rats via hypoglycemic and anti-inflammatory mechanism

Background: receptor advanced glycation end products (rage) activation plays an essential role in diabetic retinopathy (dr) progression. this study was aimed to explore the role of anti-rage antibodies (rage antagonists) in inhibiting dr progression through their hypoglycemic and anti inflammatory mechanism in diabetic retinopathy induced rats. methods: a total of 30 male wistar rats were randomly divided into five group. the group was consisted of normal control group, dr group without treatment, dr group with anti-rage 1 g/kg bw, 10 g/kg bw, and 100 g/kg bw. to assess the diabetic retinopathy, fundus photographs were taken every week using a camera with 16x magnification placed in front of the rat’s eyes. blood glucose was checked by the glucose oxidase-peroxidase method. retinal tnf- levels and vegf were examined using an enzyme-linked immunosorbent assay (elisa) kit. results: the finding of this study showed that anti-rage treatment at dose of 10 and 100 g/kg bw, hba1c levels were significantly higher (p< 0.05) compared to the normal control group but significantly lower (p< 0.05) than in the diabetes group. the mean blood vessel diameter in the dr+anti-rage 10 and 100 g/kg bw groups was significantly lower than in the diabetic retinopathy group (p< 0.05). the administration of anti-rage 10 and 100 g/kg bw showed the ability to significantly reduce vegf levels compared to the dr group (p< 0.05). conclusions:this study revealed at doses of 10 and 100 g/kg bw, anti-rage antibodies improved diabetic retinopathy in wistar rats through hypoglycemic effects and anti-inflammatory mechanisms.